Published in PLoS One on May 14, 2015
HSP90 and the chaperoning of cancer. Nat Rev Cancer (2005) 11.98
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A (2010) 8.05
HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol (2010) 7.16
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res (2012) 4.01
Roles of heat-shock proteins in innate and adaptive immunity. Nat Rev Immunol (2002) 3.55
Systemic lupus erythematosus. Lancet (2007) 3.32
From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol (2001) 3.02
Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc Natl Acad Sci U S A (1993) 2.79
A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res (2013) 1.90
Murine models of systemic lupus erythematosus. J Biomed Biotechnol (2011) 1.84
T cells as therapeutic targets in SLE. Nat Rev Rheumatol (2010) 1.75
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther (2011) 1.74
Taming lupus-a new understanding of pathogenesis is leading to clinical advances. Nat Med (2012) 1.63
The stress response: implications for the clinical development of hsp90 inhibitors. Curr Cancer Drug Targets (2003) 1.52
Cyclophosphamide toxicity. Characterising and avoiding the problem. Drugs (1991) 1.49
Increased levels of antibodies to heat shock proteins with increasing age in Mrl/Mp-lpr/lpr mice. Br J Rheumatol (1995) 1.48
Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Res Ther (2011) 1.37
Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum (2008) 1.27
Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus (2001) 1.18
CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance. J Clin Invest (2014) 1.14
EC144, a synthetic inhibitor of heat shock protein 90, blocks innate and adaptive immune responses in models of inflammation and autoimmunity. J Immunol (2010) 1.14
Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther (2012) 1.14
Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol (2011) 1.13
TCR ligation on CD8+ T cells creates double-negative cells in vivo. J Immunol (1998) 1.12
Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J (2007) 1.08
Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. Cancer Res (2014) 1.06
The heat-shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin suppresses glial inflammatory responses and ameliorates experimental autoimmune encephalomyelitis. J Neurochem (2006) 1.04
A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer (2013) 1.03
Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol (2012) 1.02
The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation. Cell Stress Chaperones (2000) 1.01
Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice. J Pharmacol Exp Ther (2008) 0.99
Differential heat shock protein overexpression and its clinical relevance in systemic lupus erythematosus. Ann Rheum Dis (1993) 0.97
Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. Cell Mol Immunol (2012) 0.95
Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol (2013) 0.95
Elevated levels of the 90 kDa heat shock protein (hsp90) in SLE correlate with levels of IL-6 and autoantibodies to hsp90. J Autoimmun (2001) 0.94
Abrogation of skin disease in LUPUS-prone MRL/FASlpr mice by means of a novel tylophorine analog. Arthritis Rheum (2006) 0.94
Detection of autoantibodies to the 90 kDa heat shock protein in systemic lupus erythematosus and other autoimmune diseases. Br J Rheumatol (1994) 0.94
Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus (2004) 0.93
Lupus-specific kidney deposits of HSP90 are associated with altered IgG idiotypic interactions of anti-HSP90 autoantibodies. Clin Exp Immunol (2002) 0.92
Treatment targets in systemic lupus erythematosus: biology and clinical perspective. Arthritis Res Ther (2012) 0.90
Identification of new pathogenic players in lupus: autoantibody-secreting cells are present in nephritic kidneys of (NZBxNZW)F1 mice. J Immunol (2010) 0.89
New paradigm for intrinsic function of heat shock proteins as endogenous ligands in inflammation and innate immunity. Curr Mol Med (2012) 0.88
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer. Invest New Drugs (2014) 0.87
Elevated levels of the 90 kd heat shock protein in a proportion of SLE patients with active disease. J Autoimmun (1989) 0.85
The regulation of heat shock proteins and their role in systemic lupus erythematosus. Semin Arthritis Rheum (1998) 0.85
Elevation of IL-6 in transgenic mice results in increased levels of the 90 kDa heat shock protein (hsp90) and the production of anti-hsp90 antibodies. J Autoimmun (1998) 0.83
Adverse event burden, resource use, and costs associated with immunosuppressant medications for the treatment of systemic lupus erythematosus: a systematic literature review. Int J Rheumatol (2013) 0.80
Animal models of systemic lupus erythematosus (SLE) and ex vivo assay design for drug discovery. Curr Protoc Pharmacol (2011) 0.79
Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulations. J Inflamm (Lond) (2014) 0.78
Systemic lupus erythematosus. Clin Dev Immunol (2012) 0.78
The novel HSP90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE. J Neuroimmunol (2012) 0.77
Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses. Exp Dermatol (2014) 0.77